Argent BioPharma Limited (ASX:RGT)

Market Cap	3.73M -63.1%
Revenue (ttm)	161.19K -10.7%
Net Income	-7.71M
EPS	-0.09
Shares Out	116.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,465
Open	0.0310
Previous Close	0.0300
Day's Range	0.0310 - 0.0320
52-Week Range	0.0300 - 0.1450
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Argent BioPharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company’s principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer’s. It i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RGT

Financial Performance

In fiscal year 2026, Argent BioPharma's revenue was 161,187, a decrease of -10.73% compared to the previous year's 180,565. Losses were -7.71 million, -56.79% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error